Gamma globulin therapy for chronic mononucleosis syndrome. NLM AIDSLINE Important note: Information in this article was accurate in 1987. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Gamma globulin therapy for chronic mononucleosis syndrome.

AIDS Res. 1986 Dec;2 Suppl 1:S191-5. Unique Identifier : AIDSLINE MED/87156946
DuBois RE

Abstract: Antibodies against Epstein-Barr virus, associated with antibody dependent cytotoxic cell activity, were found to be present in diminished titer in 20 of 22 patients tested with chronic mononucleosis syndrome (CMS). Gamma globulin was shown to improve symptoms in 53% of the patients treated, compared with 32% of placebo injections. 89.5% of 57 patients treated with a gamma globulin treatment program remained in the treatment program because of relief of symptoms, and only four patients dropped out because there was no relief of symptoms or side effects. Four patients experienced complete relief of symptoms following a variable length treatment program. It would appear that intramuscular gamma globulin treatment is efficacious in the treatment of CMS and that the average interval between treatments is three weeks.
Keywords: Antibodies, Viral/ANALYSIS Antibody-Dependent Cell Cytotoxicity Chronic Disease Clinical Trials Double-Blind Method Drug Administration Schedule Gamma Globulins/ADMINISTRATION & DOSAGE Herpesvirus 4, Human/IMMUNOLOGY Human *Immunization, Passive Infectious Mononucleosis/IMMUNOLOGY/*THERAPY Injections, Intramuscular Prospective Studies Random Allocation CLINICAL TRIAL JOURNAL ARTICLE

KWDantibodies,viral/analysisantibody-dependentcellcytotoxicitychronicdiseaseclinicaltrialsdouble-blindmethoddrugadministrationschedulegammaglobulins/administration&dosageherpesvirus4,human/immunologyhumanKWDimmunization,passiveinfectiousmononucleosis/immunology/KWDtherapyinjections,intramuscularprospectivestudiesrandomallocationclinicaltrialjournalarticle
870730
M8770096

Copyright © 1987 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1987. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1987. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .